On Friday, Astria Therapeutics Inc (NASDAQ: ATXS) was 7.43% up from the session before settling in for the closing price of $7.0. A 52-week range for ATXS has been $3.56 – $12.92.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 34.65% over the past five years. When this article was written, the company’s average yearly earnings per share was at -24.28%. With a float of $45.29 million, this company’s outstanding shares have now reached $56.43 million.
Astria Therapeutics Inc (ATXS) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Astria Therapeutics Inc stocks. The insider ownership of Astria Therapeutics Inc is 19.75%, while institutional ownership is 82.82%.
Astria Therapeutics Inc (ATXS) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.42 earnings per share (EPS) during the time that was better than consensus figure (set at -0.42) by 0. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.54 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -24.28% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -8.47% during the next five years compared to 34.65% growth over the previous five years of trading.
Astria Therapeutics Inc (NASDAQ: ATXS) Trading Performance Indicators
You can see what Astria Therapeutics Inc (ATXS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 14.89.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.03, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -2.24 in one year’s time.
Technical Analysis of Astria Therapeutics Inc (ATXS)
Astria Therapeutics Inc (NASDAQ: ATXS) saw its 5-day average volume 0.37 million, a positive change from its year-to-date volume of 0.36 million. As of the previous 9 days, the stock’s Stochastic %D was 92.74%.
During the past 100 days, Astria Therapeutics Inc’s (ATXS) raw stochastic average was set at 98.71%, which indicates a significant increase from 96.62% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.44 in the past 14 days, which was higher than the 0.41 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.48, while its 200-day Moving Average is $6.65. Nevertheless, the first resistance level for the watch stands at $7.78 in the near term. At $8.04, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.51. If the price goes on to break the first support level at $7.05, it is likely to go to the next support level at $6.58. The third support level lies at $6.32 if the price breaches the second support level.
Astria Therapeutics Inc (NASDAQ: ATXS) Key Stats
There are 56,435K outstanding shares of the company, which has a market capitalization of 424.39 million. As of now, sales total 0 K while income totals -94,260 K. Its latest quarter income was 0 K while its last quarter net income were -33,050 K.
